A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

Cystic fibrosis affects many parts of the body, but its effects on the lungs can be especially harmful. Cystic fibrosis is a chronic and progressive condition that causes the mucus in your lungs to be ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

In patients with CF, pre-transplant PH is associated with improved early post-transplant survival, but with poorer outcomes after 3 years.

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients with idiopathic pulmonary fibrosis in Korea.Recently, the number of patients ...

Clinical worsening also occurred less frequently with treprostinil ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...

Jascayd (nerandomilast) is a brand-name prescription oral tablet used to treat idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults by reducing inflammation and slowing lung ...

In 1945, someone diagnosed with cystic fibrosis faced extremely long odds to live a long life. Many never made it out of childhood.

Severe COVID-19 and influenza infections can epigenetically reprogram lung and immune cells, creating a pro‑tumor environment that increases lung cancer risk, but vaccines may prevent this.